# DoW Funds MediWound NexoBrid Development

On November 12, 2026, the U.S. Department of War announced an additional $3.3 million award to MediWound for a room-temperature-stable NexoBrid formulation for battlefield burn care, bringing the program budget to $21.8 million. The development is intended to continue through an Investigational New Drug application. Separately, BARDA-related NexoBrid purchases through Vericel’s contract began in Q3 2026 and are expected to continue through Q1 2027. MediWound’s quarterly revenue fell year over year from $5.4 million to $3.6 million, with the decline attributed to lower U.S. government development-services revenue; funding discussions for its planned U.S. manufacturing facility remain uncertain. The reported award and purchases are existing activities, not open solicitations.

- The additional award indicates continued federal investment in a battlefield burn-care product; the total program budget is **$21.8 million**, including the **$3.3 million** additional award.
- Procurement professionals and suppliers can distinguish the DoW-funded formulation development from BARDA-related product purchases routed through Vericel’s contract. The reported information does not identify a new competition.
- Companies supporting medical countermeasures, formulation development, or related supply chains may find the award and the expected purchasing period through Q1 2027 relevant when assessing market activity. MediWound’s planned U.S. manufacturing facility remains contingent on uncertain government funding.

**Jurisdictions:** federal
**Industries:** Healthcare, Defense & Military
**Topics:** Grants & Funding
**Published:** November 12, 2026

### Government Entities
- U.S. Department of War (DoW)
- Biomedical Advanced Research and Development Authority (BARDA)
- U.S. Food and Drug Administration (FDA)

### Vendors
- MediWound Ltd. (awardee)
- Vericel (contractor)

### Key Quotes
> We are also working diligently with the U.S. government to secure funding for our planned U.S. manufacturing facility. The timing and outcome of these funding discussions remain uncertain.
> — Ofer Gonen, Chief Executive Officer of MediWound

### Sources
- [$MDWD's quarterly revenue fell from $5.4 million to $3.6 million. The stock story is not on the revenue line.

https://t.co/lX2pOiUfsE

The revenue decline is entirely explained by one category: U.S. government development services. Those revenues depended on federally-funded pro](https://x.com/MonkofFinance/status/2120856322811769187) - twitter-fed-procurement